Login to Your Account

T-DM1 Moves from Clinic to FDA in HER2-positive mBC

By Marie Powers
Staff Writer

Tuesday, August 28, 2012

Roche Group unit Genentech Inc. moved its HER2-positive metastatic breast cancer (mBC) candidate T-DM1 (trastuzumab emtansine) to the regulators, submitting a biologics license application (BLA) for the drug to the FDA and requesting priority review.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription